You just read:

Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

News provided by

Jazz Pharmaceuticals plc

Oct 29, 2018, 08:00 ET